HMGN Polypeptides Modulate Th-1/Th-2 Balance for Enhanced Immunity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current medical treatments often face challenges due to a diminished or imbalanced immune response, particularly a shift towards a Th-2 anti-inflammatory type response, which can lead to rapid disease progression and reduced treatment effectiveness in conditions like cancer, where a Th-1 pro-inflammatory response is desired.

Innovation Solution

Administration of HMGN polypeptides, such as HMGN1, HMGN3a, HMGN3b, HMGN4, or Nsbp1, or their functional fragments to enhance antigen-specific immune responses, activate dendritic cells, and shift the Th-1/Th-2 balance towards a Th-1 type immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional medical treatments are used, then treatment can be administered, but the immune response is diminished or shifted towards Th-2 anti-inflammatory type, leading to rapid disease progression and reduced treatment effectiveness

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidimmune response balance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

HMGN polypeptides serve as intermediary substances that modulate the immune system's Th-1/Th-2 balance. The polypeptides bind to dendritic cells and T-cells, acting as mediators to shift the immune response from Th-2 dominant back towards Th-1, thereby enhancing treatment effectiveness without directly attacking the disease pathology

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the immunological parameter of Th-1/Th-2 balance by administering HMGN polypeptides. This shifts the immune system's state from a Th-2 polarized condition (associated with disease progression) to a Th-1 enhanced condition (associated with disease control), thereby resolving the contradiction between maintaining treatment effectiveness and preserving immune response balance

Inventive Principle:

Principle #35Parameter changes

2Reliability

If HMGN polypeptides are administered to enhance Th-1 immune response, then antigen-specific immune response is enhanced and dendritic cells are activated, but this may cause increased inflammation

Engineering Contradiction:

Improveimmune response enhancementVSAvoidinflammation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The HMGN polypeptides dynamically regulate the immune response by selectively enhancing Th-1 responses while maintaining control over inflammatory levels. The polypeptides' ability to bind to specific cell surface receptors allows for dynamic modulation of immune cell activation states, enhancing protective immunity while preventing excessive inflammation

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The invention converts the potentially harmful Th-2 anti-inflammatory response (which was causing disease progression) into a benefit by using HMGN polypeptides to restore appropriate Th-1 responses. The polypeptides effectively rebalance the immune system, turning the disadvantageous Th-2 dominance into an opportunity to restore healthy immune function

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS9567566B2HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants

Publication Date: 2017.02.14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

AI summary

A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.